Regeneron
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
CEOLeonard S. Schleifer
CEOLeonard S. Schleifer
Employees15,106
Employees15,106
HeadquartersTarrytown, New York
HeadquartersTarrytown, New York
Founded1988
Founded1988
Employees15,106
Employees15,106
REGN Key Statistics
Market cap73.40B
Market cap73.40B
Price-Earnings ratio17.99
Price-Earnings ratio17.99
Dividend yield0.13%
Dividend yield0.13%
Average volume1.01M
Average volume1.01M
High today$686.91
High today$686.91
Low today$657.00
Low today$657.00
Open price$680.61
Open price$680.61
Volume474.12K
Volume474.12K
52 Week high$1,211.20
52 Week high$1,211.20
52 Week low$642.00
52 Week low$642.00
REGN News
Seeking Alpha 10m
Regeneron falls after appeals court ruling in Eylea caseRegeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case over Regeneron's blockbuster Eylea...
TipRanks 17m
Appeals court upholds denial of Regeneron motion for injunction against AmgenRegeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying Regeneron’s motion f...
TipRanks 5d
Regeneron, Sanofi presents results from ADEPT Phase 2/3 trial on DupixentRegeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixe...
Analyst ratings
67%
of 27 ratingsBuy
66.7%
Hold
29.6%
Sell
3.7%